Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 2Phase NA 1

Status

Recruiting 8Completed 5Unknown 3Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5Observational 2

Sponsor

Cancer Type

Thoracic 5

Conditions

Breast Neoplasms 4997Neoplasms 4192Prostatic Neoplasms 2426Carcinoma, Non-Small-Cell Lung 2261Colorectal Neoplasms 2050Lung Neoplasms 1703Multiple Myeloma 1454Lymphoma 1403Leukemia, Myeloid, Acute 1379Neoplasm Metastasis 1372Melanoma 1269Pancreatic Neoplasms 1200Leukemia 1194Ovarian Neoplasms 1190Lymphoma, Non-Hodgkin 1128Precursor Cell Lymphoblastic Leukemia-Lymphoma 1088Head and Neck Neoplasms 1055Leukemia, Lymphocytic, Chronic, B-Cell 994Lymphoma, Follicular 896Colonic Neoplasms 893Brain Neoplasms 875Stomach Neoplasms 854Recurrence 848Carcinoma, Hepatocellular 845Glioblastoma 837Lymphoma, Large B-Cell, Diffuse 770Rectal Neoplasms 758Uterine Cervical Neoplasms 725Carcinoma, Renal Cell 704Hodgkin Disease 696

Interventions

toripalimab 2sintilimab 2Pemetrexed 1Paclitaxel 1Injections 1Etoposide 1Docetaxel 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Completed × Interventional × Advanced Lung Cancer × Clear all
NCT05664971 2025-12-02

JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer

Shanghai Junshi Bioscience Co., Ltd.

Phase 1/2 Completed
119 enrolled
Thoracic

Advanced Lung Cancer

NCT05000684 2025-02-20

Study of JS004 Combined With Toripalimab for Advanced Lung Cancer

Shanghai Junshi Bioscience Co., Ltd.

Phase 1/2 Completed
67 enrolled
Thoracic

Advanced Lung Cancer

NCT04672356 2023-06-22

A Study to Evaluate the Safety , Tolerability and Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced Lung Cancer

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1 Completed
19 enrolled
Thoracic

Advanced Lung Cancer

NCT04672369 2023-06-22

A Study to Evaluate the Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced NSCLC

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1 Completed
42 enrolled
Thoracic

Advanced Lung Cancer

NCT02801734 2018-03-29

EQUIP

National Cancer Centre, Singapore

Phase NA Completed
69 enrolled
Thoracic

Advanced Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡